IGNYTA INC (RXDX)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Jonathan E. Lim
Employees:
108
4545 TOWNE CENTRE COURT, SAN DIEGO, CA 92121
(858) 255-5959

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Ignyta, Inc. is a precision oncology biotechnology company that engages in the discovering, acquiring, developing and commercializing targeted new drugs for cancer patients. It plans focus on two product candidates: entrectinib, a tyrosine kinase inhibitor directed to the Trk family tyrosine kinase receptors ROS1 and ALK proteins, which is in two Phase I/II clinical studies in molecularly defined patient populations for the treatment of solid tumors; and RXDX-103, a development program targeting the cell division cycle 7-related, or CDC7, protein kinase. The company was founded by Jonathan E. Lim on October 31, 2013 and is headquartered in San Diego, CA.

Data derived from most recent annual or quarterly report
Market Cap 1.678 Billion Shares Outstanding66.338 Million Avg 30-day Volume 2.631 Million
P/E Ratio0.0 Dividend Yield0.0 EPS
Price to Revenue0.0 Debt to Equity0.0 EBITDA0
Price to Book Value0.0 Operating Margin0.0 Enterprise Value0
Current Ratio0 EPS Growth0 Quick Ratio0
1 Yr BETA 1.4383 52-week High/Low 0.0 / Profit Margin0.0
Operating Cash Flow Growth0.0 Altman Z-Score0.0 Free Cash Flow to Firm 0

Are you looking for this stock instead?

View SEC Filings from RXDX instead.

View recent insider trading info

Funds Holding RXDX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding RXDX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Events (8k)

  • 8-K: filed on 2018-02-08:
    Item 1.02: Termination of a Material Definitive Agreement
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-12-28:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-12-22:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-11-07:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-10-20:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-10-18:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-10-17:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-09-11:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-09-06:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-08-18:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    CEDARS SINAI INTELLECTUAL PROPERTY CO

    • 10% Owner
    5,008,508 2021-06-25 0

    HASSAN FRED

    • Director
    0 2021-05-14 0

    LAUR JAMES

    • Director
    40,000 2021-04-14 0

    HENDRIX MARTIN

    • Director
    40,000 2021-04-14 0

    CEDARS SINAI MEDICAL CENTER

    • 10% Owner
    5,008,508 2021-03-16 0

    YAMADA TADATAKA

    • Director
    • AND CHAIRMAN OF THE BOARD
    13,333 2021-03-16 0

    NESTLE SA

    SOCIETE DES PRODUITS NESTLE S.A.

    • 10% Owner
    0 2021-03-11 0

    POINT72 BIOTECH PRIVATE INVESTMENTS, LLC

    DIFFERENTIATED VENTURES INVESTMENTS, LLC

    72 INVESTMENT HOLDINGS, LLC

    COHEN STEVEN A/SAC CAPITAL MGMT LP

    • 10% Owner
    0 2021-03-11 0

    PERCEPTIVE ADVISORS LLC

    PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

    EDELMAN JOSEPH

    • 10% Owner
    0 2021-03-11 0

    PAPA JOSEPH C

    • Director
    0 2021-03-11 0

    SZELA MARY T

    • Director
    0 2021-03-11 0

    SWAIN JUDITH L

    • Director
    0 2021-03-11 0

    ADAMS HELEN C.

    • Director
    0 2021-03-11 0

    RTW INVESTMENTS, LP

    WONG RODERICK

    • 10% Owner
    0 2021-03-11 0

    CORMORANT ASSET MANAGEMENT, LP

    CHEN BIHUA

    CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP

    CORMORANT PRIVATE HEALTHCARE FUND III LP

    • Director
    • 10% Owner
    0 2021-03-11 0

    ANDREWS TIMOTHY K. GENERAL COUNSEL

    • Officer
    0 2021-03-11 0

    MARSHALL KEITH W CHIEF FINANCIAL OFFICER

    • Officer
    0 2021-03-11 0

    STENHOUSE MARK CHIEF OPERATING OFFICER

    • Officer
    0 2021-03-11 0

    MCKENNA MARK C. PRESIDENT AND CEO

    • Officer
    • Director
    0 2021-03-11 0

    LUO ALLISON CHIEF MEDICAL OFFICER

    • Officer
    117,708 2021-03-11 0

    LIM JONATHAN E PRESIDENT, CEO & DIRECTOR

    • Officer
    • Director
    • 10% Owner
    No longer subject to file 2018-02-08 0

    FREDDO JAMES L

    • Director
    No longer subject to file 2018-02-08 0

    DREISMANN HEINER

    • Director
    No longer subject to file 2018-02-08 0

    KUHLEN CHRISTIAN V GENERAL COUNSEL AND SECRETARY

    • Officer
    No longer subject to file 2018-02-08 0

    CASDIN ALEXANDER W.

    • Director
    No longer subject to file 2018-02-08 0

    HOERTER STEVEN L.

    • Director
    No longer subject to file 2018-02-08 0

    MULTANI PRATIK S CHIEF MEDICAL OFFICER

    • Officer
    No longer subject to file 2018-02-08 0

    BRISTOL JAMES A

    • Director
    No longer subject to file 2018-02-08 0

    HORNBY ZACHARY CHIEF OPERATING OFFICER

    • Officer
    No longer subject to file 2018-02-08 0

    CHACKO JACOB CHIEF FINANCIAL OFFICER

    • Officer
    No longer subject to file 2018-02-08 0

    START VALERIE DENISE HARDING SVP, CHEMISTRY, MFG & CONTROLS

    • Officer
    No longer subject to file 2018-02-08 0

    MCCARTHY WILLIAM R CHIEF BUSINESS OFFICER

    • Officer
    No longer subject to file 2018-02-08 0

    ONAITIS MATTHEW GENERAL COUNSEL AND SECRETARY

    • Officer
    46,400 2016-01-07 0

    BILINSKY IGOR GM, IMMUNO-ONCOLOGY/SVP SP OPS

    • Officer
    6,960 2016-01-07 0

    WILD ROBERT SR. VP, RESEARCH AND CSO

    • Officer
    13,200 2016-01-07 0

    PARKER BERNARD CHIEF COMMERCIAL OFFICER

    • Officer
    0 2015-07-22 0

    CEPHALON INC

    TEVA PHARMACEUTICAL INDUSTRIES LTD

    • 10% Owner
    3,000,000 2015-03-17 0

    SENDEROWICZ ADRIAN CHIEF MEDICAL OFFICER

    • Officer
    0 2015-01-08 0

    CITY HILL VENTURE PARTNERS I, LLC

    • 10% Owner
    3,316,668 2014-03-13 0

    ZAKNOEN SARA CHIEF MEDICAL OFFICER

    • Officer
    0 2014-03-13 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments